Draganfly to Present at Centurion One Los Angeles Summit 2024
May 29, 2024 07:15 ET
|
Draganfly Inc
CEO Cameron Chell to Highlight the Role of Drones and Draganfly in the New Global Economic and Political Reality Los Angeles, CA, May 29, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO; CSE:...
Ocugen to Present at BIO International Convention 2024
May 29, 2024 07:15 ET
|
Ocugen
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
May 29, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 29, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Assertio Announces the Appointment of Brendan P. O’Grady as New CEO
May 29, 2024 07:00 ET
|
Assertio Holdings, Inc.
Assertio appoints Brendan P. O'Grady as CEO
Balchem Corporation to Present at the Wells Fargo Industrials Conference on June 12, 2024
May 29, 2024 07:00 ET
|
Balchem Corporation
Balchem Corporation to Present at the Wells Fargo Industrials Conference on June 12, 2024
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
May 29, 2024 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
May 29, 2024 07:00 ET
|
PMV Pharmaceuticals, Inc.
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation...
Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
May 29, 2024 07:00 ET
|
Predictive Oncology Inc.
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond Vennare, Chief Executive...
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 29, 2024 07:00 ET
|
Immunocore Holdings plc
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,...